Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TANGUY YANN LIM-SEIWERT

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1043340292
CMS profile
933963
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$53,429.68

68 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Seagen Inc. $8,762.06 7
Regeneron Pharmaceuticals, Inc. $8,048.91 13
EMD Serono, Inc. $7,956.85 5
AstraZeneca Pharmaceuticals LP $6,600.72 12
Bayer Healthcare Pharmaceuticals Inc. $6,037.10 5
Exelixis Inc. $4,818.81 13
Merck Sharp & Dohme LLC $4,270.00 1
BioNTech SE $3,000.00 1
AstraZeneca UK Limited $2,397.50 1
E.R. Squibb & Sons, L.L.C. $1,537.73 10

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TANGUY YANN LIM-SEIWERT

NPI 1043340292 · CMS profile ID 933963

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043340292?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TANGUY YANN LIM-SEIWERT, NPI 1043340292, CMS profile ID 933963. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043340292?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). TANGUY YANN LIM-SEIWERT, NPI 1043340292, CMS profile ID 933963. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043340292?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
TANGUY YANN LIM-SEIWERT, NPI 1043340292, CMS profile ID 933963, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1043340292?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

68 matching records · $53,429.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 68 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–68 of 68.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $456.9505/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000699997 CMS
EMD Serono, Inc. $159.2304/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032381847 CMS
EMD Serono, Inc. $61.9304/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032381872 CMS
EMD Serono, Inc. $113.7904/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032384087 CMS
EMD Serono, Inc. $21.9004/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032381821 CMS
Merck Sharp & Dohme LLC $4,270.0003/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048657955 CMS
AstraZeneca Pharmaceuticals LP $73.6103/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011844511 CMS
AstraZeneca Pharmaceuticals LP $72.1703/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011274151 CMS
AstraZeneca Pharmaceuticals LP $2.3003/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011330211 CMS
AstraZeneca Pharmaceuticals LP $73.6103/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012045325 CMS
AstraZeneca Pharmaceuticals LP $70.0603/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011421093 CMS
AstraZeneca Pharmaceuticals LP $96.5603/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011751863 CMS
AstraZeneca Pharmaceuticals LP $152.0703/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012079441 CMS
AstraZeneca Pharmaceuticals LP $70.7203/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014214675 CMS
AstraZeneca Pharmaceuticals LP $72.1703/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014550533 CMS
AstraZeneca Pharmaceuticals LP $469.0903/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011770835 CMS
AstraZeneca Pharmaceuticals LP $2,708.3603/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011875293 CMS
AstraZeneca Pharmaceuticals LP $2,740.0002/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015363235 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $94,523.49 69
PY2020 $32,443.19 13
PY2021 $30,840.00 10
PY2022 $53,285.53 22
PY2023 $53,429.68 68
PY2024 $18,470.00 6
PY2025 $18,457.89 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,985.80 5
PY2025 Principal investigator $1,558,423.33 19
PY2024 Recipient $5,400.00 2
PY2024 Principal investigator $1,109,644.97 65
PY2023 Principal investigator $362,197.08 23
PY2022 Recipient $4,200.00 1
PY2022 Principal investigator $353,432.98 20
PY2021 Principal investigator $385,940.67 18
PY2020 Principal investigator $145,977.45 5
PY2019 Principal investigator $419,641.95 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,179.20 12/17/2025 Non-covered Recipient Entity
JHU SCHOOL OF MEDICINE
A PHASE II CLINICAL TRIAL OF CEMIPIMULAB-CHEMOTHERAPY FOLLOWED BY BIOMARKER GUIDED DEESCALATED CURATIVE INTENT LOCOREGIONAL TREATMENT FOR PATIENTS WITH ADVANCED HPV RELATED H&N CANCER No dispute reported 06/30/2026 1184276526
Principal investigator 1 ABBVIE INC. $5,751.54 12/04/2025 Non-covered Recipient Entity
THE JOHNS HOPKINS UNIVERSITY
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202527474
Principal investigator 1 PFIZER INC. $10,932.00 11/17/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228738953
Principal investigator 1 PFIZER INC. $23,463.00 11/10/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228739319
Principal investigator 1 ABBVIE INC. $12,916.38 10/09/2025 Non-covered Recipient Entity
THE JOHNS HOPKINS UNIVERSITY
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202516253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47,435.25 10/02/2025 Non-covered Recipient Entity
JHU SCHOOL OF MEDICINE
A PHASE II CLINICAL TRIAL OF CEMIPIMULAB-CHEMOTHERAPY FOLLOWED BY BIOMARKER GUIDED DEESCALATED CURATIVE INTENT LOCOREGIONAL TREATMENT FOR PATIENTS WITH ADVANCED HPV RELATED H&N CANCER No dispute reported 06/30/2026 1184244497
Principal investigator 1 Merck Sharp & Dohme LLC $1,057,773.56 08/31/2025 Non-covered Recipient Entity
Johns Hopkins University
Neoadjuvant Pembrolizumab and IO102/103 prior to curative-intent surgical care for squamous cell carcinoma of the head and neck (SCCHN): The KIEO trial. No dispute reported 06/30/2026 1232935845
Principal investigator 1 PFIZER INC. $837.00 07/28/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228785670
Principal investigator 1 PFIZER INC. $20,573.00 06/16/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228777359
Recipient BioNTech SE $3,300.00 06/12/2025 Covered Recipient Physician BNT113-01 No dispute reported 06/30/2026 1249019302
Principal investigator 1 PFIZER INC. $837.00 06/09/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228776033
Recipient Regeneron Pharmaceuticals, Inc. $575.44 06/02/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184119725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27,008.33 05/29/2025 Non-covered Recipient Entity
JHU SCHOOL OF MEDICINE
A PHASE II CLINICAL TRIAL OF CEMIPIMULAB-CHEMOTHERAPY FOLLOWED BY BIOMARKER GUIDED DEESCALATED CURATIVE INTENT LOCOREGIONAL TREATMENT FOR PATIENTS WITH ADVANCED HPV RELATED H&N CANCER No dispute reported 06/30/2026 1184200197
Principal investigator 1 PFIZER INC. $4,642.00 05/05/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228762915
Principal investigator 1 PFIZER INC. $3,470.00 05/05/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228764562
Principal investigator 1 Merck Sharp & Dohme LLC $299,672.28 04/16/2025 Non-covered Recipient Entity
Johns Hopkins University
Neoadjuvant Pembrolizumab and IO102/103 prior to curative-intent surgical care for squamous cell carcinoma of the head and neck (SCCHN): The KIEO trial. No dispute reported 06/30/2026 1232935685
Principal investigator 1 Merck Sharp & Dohme LLC $27,137.44 04/16/2025 Non-covered Recipient Entity
John Hopkins University Central Lockbox
A Phase II Multi-Arm basket Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-Line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer NSCLC, Squamous Cell Carcinoma of Head or Neck SCCHN, or Metastatic Urothelial Bladder Cancer mUBC No dispute reported 06/30/2026 1232936136
Principal investigator 1 PFIZER INC. $837.00 04/14/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228797225
Recipient Regeneron Pharmaceuticals, Inc. $534.45 03/27/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184119723
Recipient Regeneron Pharmaceuticals, Inc. $366.45 03/25/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184119721
Principal investigator 1 Genentech, Inc. $7,994.00 03/20/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
Atezo tira and atezo placebo in 1L recurrent metastatic SCCHN No dispute reported 06/30/2026 1211618519
Principal investigator 1 PFIZER INC. $2,409.35 03/10/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228778931
Principal investigator 1 PFIZER INC. $3,555.00 02/18/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228794732
Recipient Regeneron Pharmaceuticals, Inc. $209.46 02/06/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184119719